# A Study of PLB-002 in Advanced Solid Tumors

Source: https://onco.cc/trials/nct07304128/  
OnCo record `nct07304128` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of PLB-002 run by Primelink BioTherapeitics(ShenZhen) Limited, now recruiting.

## Summary

A Study of PLB-002 in Advanced Solid Tumors is a phase 1 interventional study registered as NCT07304128 by Primelink BioTherapeitics(ShenZhen) Limited, with 100 participants planned, started 2026-02-06. Conditions recorded: Advanced Solid Tumor. Interventions recorded: PLB-002.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07304128
- Phase: 1
- Setting: A Phase 1, Open-Label, Multi-Center, Dose Escalation and Expansion Study of PLB-002 (Anti-Claudin 6 ADC) in Adults With Advanced Solid Tumors
- Sponsor: Primelink BioTherapeitics(ShenZhen) Limited
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT07304128: https://clinicaltrials.gov/study/NCT07304128

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [PLB-002](https://onco.cc/drugs/plb-002/)
- companies: [PrimeLink BioTherapeutics](https://onco.cc/companies/primelink-biotherapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07304128.json